Disclosure Plus

Chabiotech Co.,Ltd. Decides to Acquire Cha Healthcare Shares Worth 80.3 Billion Won

Shin Ha-yeon
2026-08-18 17:32:03
[Edaily Reporter Shin Ha-yeon ] Chabiotech Co.,Ltd.(085660)announced on the 18th that it has decided to acquire 2,524,051 shares of its subsidiary, Cha Healthcare, for 80,316,930,000 won. The acquisition amount represents 7.96% of the company’s equity.

The acquisition will be conducted via an over-the-counter purchase, and the scheduled acquisition date is September 10. Upon completion of the acquisition, Chabiotech Co.,Ltd.’s holdings in Cha Healthcare will increase to 14,168,288 shares, bringing its ownership stake to 60.1%.

The company explained that it decided to purchase Cha Healthcare’s convertible preferred shares after DaishinSecurities-Y2HC New Technology Investment Fund No. 1 and HANWHA INVESTMENT & SECURITIES, both shareholders of Cha Healthcare, exercised their right to demand the purchase of shares.

Economy

Corporation

IT·Science

Economy

Shifting from Short-Term to Medium- and Long-Term... Appeal of Commercial Paper as a Funding Source Plummets

Fluctuations in credit spreads serve as an indicator of investor sentiment and capital flows in the corporate bond market. “Credit Signal” provides an intuitive analysis of the market’s overall trends…
2026-10-23 17:57:04

Corporation

Jeong Yong-jin Starts by Replacing E-MART Co., Ltd.’s CEO… Appoints Entire Executive Team in Their 40s

Shinsegae Co.,Ltd Chairman Chung Yong-jin is returning to the forefront of management at E-MART Co., Ltd.(139480). Unlike in 2013, when he stepped down as a registered director and entrusted the busin…
2026-10-23 14:55:06

IT·Science

HANALL BIOPHARMA CO.,LTD’s ‘Batoclimab’ Receives First New Drug Approval in China Nine Years After Technology Export

“Batoclimab,” a treatment for autoimmune diseases developed by HANALL BIOPHARMA CO.,LTD(009420), has received new drug approval in China. This comes approximately nine years after the company licensed…
2026-10-23 21:05:02